Autoantibody evaluation in idiopathic inflammatory myopathies

Area of Science:

• Rheumatology and Immunology
• Neurology
• Dermatology

Background:

• Idiopathic inflammatory myopathies (IIM), or myositis, encompass a spectrum of autoimmune diseases.
• These conditions are defined by muscle inflammation, potential skin involvement, and varied extramuscular manifestations.
• IIM presents with diverse risks for malignancy and treatment responses, necessitating precise classification.

Purpose of the Study:

• To provide a comprehensive overview of current myositis-specific antibodies (MSAs) and myositis-associated autoantibodies.
• To explore the role of these autoantibodies in the classification, diagnosis, and prognosis of IIM.
• To highlight detection pathways and interpretative considerations for clinical application.

Main Methods:

• Review of contemporary literature on autoantibodies in idiopathic inflammatory myopathies.
• Analysis of clinico-serologic categorization of IIM based on autoantibody profiles.
• Discussion of diagnostic and prognostic implications of MSAs and myositis-associated autoantibodies.

Main Results:

• Contemporary classification stratifies IIM into five main clinical groups using autoantibodies.
• Myositis-specific antibodies (MSAs) and myositis-associated autoantibodies are key biomarkers for IIM subtyping.
• These antibodies offer a cost-effective, personalized approach to IIM evaluation, potentially guiding diagnosis and prognosis.

Conclusions:

• Autoantibodies are crucial for classifying IIM into distinct subgroups like anti-synthetase syndrome and dermatomyositis.
• The integration of MSAs and myositis-associated autoantibodies enhances personalized patient management in IIM.
• Further research is needed to refine detection and interpretation for routine clinical utility in myositis.